ArticleBMC infectious diseases2026
Temporal dynamics and predictors of carbapenem-resistant gram-negative bacteria in bloodstream infections in hematological patients.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBloodstream infections (BSIs) caused by carbapenem-resistant (CR) Gram-negative bacteria (GNB) represent a critical challenge in febrile neutropenia (FN). This study investigated temporal resistance trends, clinical features, and predictors of CR-GNB BSIs in hematology patients over a 10-year period.
methodsA retrospective cohort analysis was conducted on GNB BSIs in febrile neutropenic patients hospitalized between 2014 and 2025. Microbiologic, demographic, and clinical data were collected and analyzed.
resultsA total of 604 patients with hematologic malignancies experienced 975 FN episodes with microbiologically confirmed BSIs, yielding 1096 isolates. Of these episodes, 57.5% occurred in males, with a median patient age of 49.5 years (IQR: 34–60.5). GNB accounted for 732 (66.9%) isolates. Among all GN isolates, 22.8% were CR-GNB. CR-GNB BSIs were significantly more common during Period 1 (OR: 0.492; 95% CI: 0.277–0.876 for Period 2; OR: 0.496; 95% CI: 0.285–0.864 for Period 3; OR: 0.455; 95% CI: 0.258–0.804 for Period 4). Independent predictor factors for CR-GNB BSIs included prior CRE colonization or infection within the last year (OR: 3.723; 95% CI: 2.218–6.251), intravenous antibiotic use within the preceding three months (OR: 1.825; 95% CI: 1.076–3.094), and geographic origin from Asia (OR: 2.308; 95% CI: 1.065–5.002).
conclusionsOur findings highlight a reduction in both carbapenem resistance and mortality over time, reflecting improvements in antimicrobial stewardship and infection control. Patients with recent antibiotic exposure or prior CRE colonization at high risk and warrant close monitoring and early targeted therapy. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.